Cover Image
Market Research Report
Product code

North America Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

Published: | Mordor Intelligence Pvt Ltd | 70 Pages | Delivery time: 2-3 business days


Back to Top
North America Anesthesia Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
Published: February 1, 2020
Mordor Intelligence Pvt Ltd
Content info: 70 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents

The North American anesthesia drugs market is expected to register a CAGR of nearly 3.5% during the forecast period, 2019-2024.

According to the US Census Bureau's Statistics, as of 2017, the total number of people aged 65 years and older had exceeded 50 million, and between 2020 and 2030, the number of elderly people is projected to increase by almost 18 million. Although much smaller in total size, the number of people aged 85 years and older is expected to be more than triple from an estimated 6 million in the present scenario, to nearly 20 million by 2060. With rising aged population, there will be an increased proportion of elderly patients (greater than 65 years), and up to 50% of surgeries will be performed in these patients. Moreover, elderly patients are likely to be having higher perioperative morbidity and mortality. The older population tends to have more critical diseases, which puts them at an increased risk for perioperative morbidity. The geriatric population is also at a higher risk of organ function failures, as there are changes in the pharmacokinetics and pharmacodynamics related to age and organ function. As the proportion of older patients increases, there will be an increased patient risk with cardiac and pulmonary diseases, alterations in kidney and liver function, and respiratory and urinary tract complications. Additionally, the older population tends to have more eye problems, including presbyopia, floaters, dry eyes, tearing, cataracts, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and retinal detachment among other problems. Thus, the growth in the geriatric population is likely to result in a significant increase in the demand for the surgeries. The overall increase in the number of surgeries performed will have a strong impact on the anesthetics market, as anesthetic devices are used in surgical procedures to reduce the pain during surgery.

Key Market Trends

Propofol Sub-segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment

Propofol is a drug that has been used for a long time for various surgical procedures requiring anesthesia. Teva Pharmaceuticals had stopped manufacturing propofol for a particular time; however, the drug returned to the market in 2013. Hospira is another major player in the propofol sub-segment. In 2015, Pfizer acquired Hospira and created a leading global established pharmaceutical (GEP) business. Some of the companies who manufacture propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi, having global presence and well-estbalished distribution channel for the drugs in this segment. The drug is always in demand in the market for utilization in different surgeries, and is expected to witness rapid growth in the coming years.

Competitive Landscape

The North American anesthesia drugs market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Companies, like Baxter International, Fresenius SE & Co. KGaA, Eisai Co. Ltd, Roche Holding AG, and B. Braun Melsungen AG, hold substantial market shares in the anesthesia drugs market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 55273

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Surgeries
    • 4.2.2 Increasing Geriatric Population
    • 4.2.3 New Approvals of Anesthetic Drugs
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of General Anesthetics
    • 4.3.2 Regulatory Issues
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Drug Type
    • 5.1.1 General Anesthesia Drugs
      • Propofol
      • Sevoflurane
      • Desflurane
      • Dexmedetomidine
      • Remifentanil
      • Midazolam
      • Isoflurane
      • Other General Anesthesia Drugs
    • 5.1.2 Local Anesthesia Drugs
      • Bupivacaine
      • Ropivacaine
      • Lidocaine
      • Chloroprocaine
      • Articaine
      • Benzocaine
      • Other Local Anesthesia Drugs
  • 5.2 By Route of Administration
    • 5.2.1 Inhalation
    • 5.2.2 Injection
    • 5.2.3 Other Routes of Administration
  • 5.3 By Application
    • 5.3.1 General Surgeries
    • 5.3.2 Plastic Surgery
    • 5.3.3 Cosmetic Surgeries
    • 5.3.4 Dental Surgeries
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico


  • 6.1 Company Profiles
    • 6.1.1 Aspen Holdings
    • 6.1.2 AbbVie Inc.
    • 6.1.3 AstraZeneca
    • 6.1.4 Baxter International
    • 6.1.5 B. Braun Melsungen AG
    • 6.1.6 Eisai Co. Ltd
    • 6.1.7 Pfizer Inc.
    • 6.1.8 F. Hoffmann-La Roche AG
    • 6.1.9 Fresenius SE & Co. KGaA
    • 6.1.10 Novartis AG (Sandoz)
    • 6.1.11 Piramal Enterprises Limited